论文部分内容阅读
钙调素拮抗剂的抑癌作用及对化疗药的增效作用已有报道.本实验观察新合成钙调素拮抗剂O-4-乙氧基-丁基小柏胺(EBB)单独或与博莱霉素(BLM)联合应用,对小鼠肝癌的对抗作用. 以小鼠肝癌细胞(Hepatoma-22)为靶细胞,每孔5×10~4个/ml,与不同浓度EBB和BLM孵育72h后,作细胞计数,求得IC 50分别为1.3μg/ml和1.0μg/ml;每孔5×10~3个/0.1ml,与EBB和BLM孵育24h.用~3H-TdR参入法(0.2μCi/0.1ml)求得IC_(50)分别为1.0μg/ml及0.7μg/ml.EBB
The tumor suppressing effect of calmodulin antagonists and the synergistic effect on chemotherapeutic agents have been reported. This experiment observed the newly synthesized calmodulin antagonist O-4-ethoxy-butylberbylamine (EBB) alone or with Bo Combined use of leucomycin (BLM) to fight hepatocarcinoma in mice. Hepatoma-22 cells were used as target cells, 5×10 4 cells/ml per well, incubated with different concentrations of EBB and BLM for 72 h. After cell counting, IC50s were determined to be 1.3 μg/ml and 1.0 μg/ml, respectively; 5×10 3/0.1 ml per well, incubated with EBB and BLM for 24 h, with the addition of ~3H-TdR (0.2 μCi/0.1 ml) IC_(50) were found to be 1.0 μg/ml and 0.7 μg/ml, respectively.